2023
Chemical Complementarity of Breast Cancer Resident, T-Cell Receptor CDR3 Domains and the Cancer Antigen, ARMC3, is Associated With Higher Levels of Survival and Granzyme Expression
Pakasticali N, Chobrutskiy A, Patel D, Hsiang M, Zaman S, Cios K, Blanck G, Chobrutskiy B. Chemical Complementarity of Breast Cancer Resident, T-Cell Receptor CDR3 Domains and the Cancer Antigen, ARMC3, is Associated With Higher Levels of Survival and Granzyme Expression. Cancer Informatics 2023, 22: 11769351231177269. PMID: 37313373, PMCID: PMC10259117, DOI: 10.1177/11769351231177269.Peer-Reviewed Original ResearchCancer-testis antigensCancer antigensBreast cancer antigensT cell receptorGranzyme expressionImmune biomarkersCancer immunotherapyPatient outcomesGranzyme BCandidate antigensTestis antigensAdaptive immune receptorsAntigenCDR3 domainsImmune receptorsTumor gene expression dataReceptorsSurvivalAntigen bindingRegion 3Integration of itemsHigh levelsImmunotherapyBreast cancer datasetExpression correlation
2019
Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma
Chobrutskiy BI, Yeagley M, Tipping P, Zaman S, Diviney A, Patel DN, Falasiri S, Uversky VN, Blanck G. Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma. Oncogene 2019, 39: 1773-1783. PMID: 31740784, DOI: 10.1038/s41388-019-1101-2.Peer-Reviewed Original ResearchConceptsLow-grade gliomasComplementarity-determining region 3T cell receptor beta chainImmune responseGrade gliomasIDH1 mutantChronic inflammationReceptor beta chainCancer immunologyLGG prognosisNRAS mutantsSurvival rateCancer developmentCDR3 domainsGliomasImmune receptorsBeta chainAnticancer processesSurvival